Explore the words cloud of the EuroNeurotrophin project. It provides you a very rough idea of what is the project "EuroNeurotrophin" about.
The following table provides information about the project.
ETHNIKO IDRYMA EREVNON
|Coordinator Country||Greece [EL]|
|Total cost||3˙555˙758 €|
|EC max contribution||3˙555˙758 € (100%)|
1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
|Duration (year-month-day)||from 2018-01-01 to 2021-12-31|
Take a look of project's partnership.
|1||ETHNIKO IDRYMA EREVNON||EL (ATHINA)||coordinator||484˙773.00|
|2||AvantiCell Science Ltd||UK (AYR)||participant||546˙575.00|
|3||HITS GGMBH||DE (HEIDELBERG)||participant||498˙432.00|
|4||IDRYMA TECHNOLOGIAS KAI EREVNAS||EL (IRAKLEIO)||participant||484˙773.00|
|5||THE UNIVERSITY OF SHEFFIELD||UK (SHEFFIELD)||participant||273˙287.00|
|6||UNIVERSITE DE CAEN NORMANDIE||FR (CAEN CEDEX 5)||participant||262˙875.00|
|7||UNIVERSITA DEGLI STUDI DI SIENA||IT (SIENA)||participant||258˙061.00|
|8||STICHTING VU||NL (AMSTERDAM)||participant||255˙374.00|
|9||TECHNISCHE UNIVERSITAET DRESDEN||DE (DRESDEN)||participant||249˙216.00|
|10||ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON||EL (ATHINA)||participant||242˙386.00|
|11||ACCELOPMENT AG||CH (ZUERICH)||partner||0.00|
|12||Innovative Technologies in Biological Systems||ES (Derio)||partner||0.00|
|13||Novartis (ΕλλÎ¬ς) Α.Ε.Β.Ε.||EL (Metamorphosis)||partner||0.00|
|14||PANEPISTIMIO KRITIS||EL (RETHIMNO)||partner||0.00|
|15||Peakdale Molecular Limited||UK (Chapel-en-le-Frith)||partner||0.00|
|16||RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG||DE (HEIDELBERG)||partner||0.00|
|17||Ventac A/S||DK (Hoersholm)||partner||0.00|
Neurodegenerative diseases (ND) like AD, PD, MS and ALS/MND are on the rise in developed societies worldwide. Currently, there exists no cure for any ND, and most of the available drugs fail to tackle ND pathogenesis. Preclinical studies point to the therapeutic potential of neurotrophins, which have been shown to control a number of aspects of survival, development and function of neurons. However, the poor pharmacokinetic properties of neurotrophins render their use as drugs prohibitive. The key idea behind this project is to address this limitation by developing novel small molecule, neurotrophin mimetics with favourable profiles of stability, tissue penetration and targeted biological actions. We are motivated by seminal (patented) results of beneficiaries NHRF and FORTH, who recently demonstrated promising effects of small neurotrophin mimetics in neuroprotection and neurogenesis. EuroNeurotrophin will be the first European consortium to study small molecule neurotrophin mimetics in depth, use them as molecular probes to interrogate neurotrophins, and emphasise their clinical translation. This approach requires highly skilled researchers that have a deep understanding of neurotrophins, comprehend all steps of drug discovery and development for ND, and possess the necessary skills to translate results into novel therapies. The network has been designed to address the need for the development of new ND treatments through the collaborative training of 14 early-stage researchers. It builds on previous successful collaborations enriched with key specialists, and consists of 12 leading European research groups and 6 private companies of complementary expertise covering all steps of drug discovery and development. Collectively we will (a) conduct a unique training programme that could not be achieved by doctoral training within a single academic institution and (b) accelerate the translation of identified drug candidate molecules into the market.
|year||authors and title||journal||last update|
Athanasios Ziogas, Tomoki Maekawa, Johannes R. Wiessner, Thi Trang Le, David Sprott, Maria Troullinaki, Ales Neuwirth, Vasiliki Anastasopoulou, Sylvia Grossklaus, Kyoung-Jin Chung, Markus Sperandio, Triantafyllos Chavakis, George Hajishengallis, Vasileia Ismini Alexaki
DHEA Inhibits Leukocyte Recruitment through Regulation of the Integrin Antagonist DEL-1
published pages: 1214-1224, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1900746
|The Journal of Immunology 204/5||2020-03-11|
Canelif Yilmaz, Kanelina Karali, Georgia Fodelianaki, Achille Gravanis, Triantafyllos Chavakis, Ioannis Charalampopoulos, Vasileia Ismini Alexaki
Neurosteroids as regulators of neuroinflammation
published pages: 100788, ISSN: 0091-3022, DOI: 10.1016/j.yfrne.2019.100788
|Frontiers in Neuroendocrinology 55||2020-03-11|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EURONEUROTROPHIN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "EURONEUROTROPHIN" are provided by the European Opendata Portal: CORDIS opendata.